1 unchanged sentence
Evaluation of Disclosure Controls and Procedures
−Removed: Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive officer and principal financial officer, to allow timely decisions regarding disclosure.
+Added: Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive officer and principal financial officer, to allow timely decisions regarding disclosure.
The Chief Executive Officer and the Chief Financial Officer have reviewed the design and effectiveness of our disclosure controls and procedures as of December 31, 2025 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.
9 unchanged sentences
In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013) (“COSO”).
+Added: Our management has performed its assessment according to the guidelines established by the Committee of Sponsoring Organizations of the Treadway Commission.
+Added: Management excluded Nevro from its assessment of internal controls over financial reporting, as it was not possible to conduct an assessment of Nevro's internal control over financial reporting in the period between the merger date and the date of management's assessment.
+Added: Nevro accounted for approximately 8.5% of total assets as of December 31, 2025 and 10.0% of revenues for the year ended December 31, 2025.
Based on the foregoing and as a result of this assessment and based on the criteria in the COSO framework, management has concluded that, as of December 31, 2025, the internal control over financial reporting of Globus was effective.
4 unchanged sentences
Other Information
−Removed: On February 18, 2024, the Company adopted an updated insider trading policy (the “ Insider Trading Policy ”) in order to facilitate the mitigation of insider trading risks within the Company.
−Removed: The Insider Trading Policy applies to all transactions in the Company’s securities by the Company’s employees, officers, directors and consultants, as well as members of their immediate families and members of their households and was designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company.
−Removed: A copy of the Insider Trading Policy is filed as Exhibit 19.1 to this Annual Report on 10-K.
−Removed: During the three months ended December 31, 2024, several of the Company's directors and officers adopted, modified or terminated a “Rule 10b5- 1 trading arrangement” or a “non-Rule 10b5- 1 trading arrangement” as each term is defined under Item 408 of Regulation S-K.
−Removed: On November 11, 2024 , Ann D.
−Removed: Rhoads , Director , adopted a trading arrangement for the sale of securities of the Company’s Class A Common that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”).
−Removed: Rhoads’ Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of February 28, 2026, or the sale of all shares subject to the plan, provides for the sale of up to 27,500 shares of Class A Common pursuant to the terms of the plan.
−Removed: On December 10, 2024 , Daniel T.
−Removed: Scavilla , the Company’s President and Chief Executive Officer , adopted a Rule 10b5-1 Trading Plan for the sale of securities of the Company’s Class A Common.
−Removed: Scavilla’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of December 31, 2025, or the sale of all shares subject to the plan, provided for the sale of up to 80,000 shares of Class A Common pursuant to the terms of the plan.
−Removed: On December 4, 2024 , Kelly Huller , Executive Vice President and General Counsel , adopted a Rule 10b5-1 Trading Plan for the sale of securities of the Company’s Class A Common.
−Removed: Kelly’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of December 31, 2025, or the sale of all shares subject to the plan, provided for the sale of up to 37,500 shares of Class A Common pursuant to the terms of the plan.
+Added: Except as set forth below, during the quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
+Added: On November 12, 2025 , Kelly G.
+Added: Huller , the Company's Executive Vice President and General Counsel , adopted a trading plan intended to satisfy the condition under Rule 10b5-1(c) of the Exchange Act.
+Added: Huller’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) February 7, 2027 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 67,500 shares of Class A Common pursuant to the terms of the plan.
+Added: On December 10, 2025 , David D.
+Added: Davidar , a member of the Board , adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act.
+Added: Davidar’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) December 31, 2026 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 36,000 shares of Class A Common pursuant to the terms of the plan.
+Added: On December 10, 2025 , Berachah Foundation (David D.
+Added: Davidar's Foundation), a foundation of a member of the Board , adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act.
+Added: The foundation’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) December 31, 2026 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 9,100 shares of Class A Common pursuant to the terms of the plan.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
5 unchanged sentences
We intend to disclose future amendments to, or waivers from, provisions of our Code of Ethics that apply to our Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, or Controller, or persons performing similar functions, within four business days of such amendment or waiver.
+Added: Insider Trading Policy
+Added: The Company has adopted insider trading policies and procedures regarding securities transactions (the “Insider Trading Policy”) that apply to all employees, officers, directors and consultants of the Company, as well as the Company itself.
+Added: The Company believes that the Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations with respect to the purchase, sale and/or other dispositions of the Company’s securities, as well as the applicable rules and regulations of the New York Stock Exchange.
+Added: A copy of the Insider Trading Policy is filed as Exhibit 19 to this Annual Report on Form 10-K.
The other information required by this Item 10 will be set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which information is incorporated herein by reference.
18 unchanged sentences
Allowance for doubtful accounts:
−Removed: (In thousands)
−Removed: to expenses
+Added: (In thousands) Beginning
+Added: of period Charged
+Added: to expenses Write-offs End
Year ended December 31, 2023 $ 4,724 $ 3,658 $ 552 $ 8,934
2 unchanged sentences
Deferred tax valuation allowance:
−Removed: (In thousands)
−Removed: to expenses
−Removed: other accounts
+Added: Additions Deductions
+Added: (In thousands) Beginning
+Added: of period Charged
+Added: to expenses Charged to
+Added: other accounts Other
+Added: deductions End
Year ended December 31, 2023 $ 5,488 $ 8,301 $ 176,974 $ — $ 190,763
9 unchanged sentences
3.1 Amended and Restated Certificate of Incorporation of Globus Medical, Inc.
−Removed: (incorporated by reference to Exhibit 3.1 of the Registrant’s Amendment No.
+Added: (incorporated by reference to Exhibit 3.1 of Globus Medical , Inc.
+Added: ’s Amendment No.
5 to the Registration Statement on Form S-1 filed with the SEC on August 2, 2012).
−Removed: Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Globus Medical, Inc., dated July 30, 2012 (incorporated by reference to Exhibit 3.2 of the Registrant’s Amendment No.
+Added: 3.2 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Globus Medical, Inc., dated July 30, 2012 (incorporated by reference to Exhibit 3.2 of Globus Medical, Inc.
+Added: ’s Amendment No.
5 to the Registration Statement on Form S-1 filed with the SEC on August 2, 2012).
−Removed: Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Globus Medical, Inc., dated August 7, 2012 (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 10-Q/A filed with the SEC on September 19, 2012).
+Added: 3.3 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Globus Medical, Inc., dated August 7, 2012 (incorporated by reference to Exhibit 3.1 of Globus Me dical Inc.
+Added: ’s Form 10-Q/A filed with the SEC on September 19, 2012).
3.4 Amended and Restated Bylaws of Globus Medical, Inc.
−Removed: effective as of May 1, 2019 (incorporated by reference to Exhibit 3.1 to our Form 10-Q/A filed with the SEC on May 2, 2019).
−Removed: Amendment to Bylaws effective as of July 31, 2021 (incorporated by reference to Exhibit 3.1 to our Form 10-Q filed with the SEC on August 4, 2021).
−Removed: Specimen Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 of the Registrant’s Amendment No.
+Added: effective as of May 1, 2019 (incorporated by reference to Exhibit 3.1 to Globus Medical, Inc.’s Form 10-Q/A filed with the SEC on May 2, 2019).
+Added: 3.5 Amendment to Bylaws effective as of July 31, 2021 (incorporated by reference to Exhibit 3.1 to Globus Medical Inc.’s Form 10-Q filed with the SEC on August 4, 2021).
+Added: 4.1 Specimen Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 of Globus Medical Inc.
+Added: ’s Amendment No.
3 to the Registration Statement on Form S-1 filed with the SEC on July 16, 2012).
−Removed: Description of Securities of the Registrant.
+Added: 4.2 Description of Securities of the Registrant (incorporated by reference to Exhibit 4.2 of Globus Medical Inc.
+Added: ’s Annual Report on Form 10-K filed with the SEC on February 20, 2025).
4.3 Indenture, dated as of March 2, 2020, between NuVasive and the Trustee (incorporated by reference to Exhibit 4.1 to NuVasive, Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
4.4 First Supplemental Indenture, dated as of September 1, 2023, among Globus, NuVasive and the Trustee (incorporated by reference to Exhibit 4.2 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on September 1, 2023).
−Removed: Form of 0.375% Convertible Senior Note due 2025 (incorporated by reference to NuVasive, Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020)
10.1 Globus Medical, Inc.
−Removed: 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of the Registrant’s Amendment No.
+Added: 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Globus Medical Inc.’s Amendment No.
1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
−Removed: Form of Incentive Stock Option Grant Notice and Incentive Stock Option Agreement under 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 of the Registrant’s Amendment No.
+Added: 10.2 Form of Incentive Stock Option Grant Notice and Incentive Stock Option Agreement under 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 of Globus Medical Inc.’s Amendment No.
1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
−Removed: Form of Nonqualified Stock Option Grant Notice and Nonqualified Stock Option Agreement under 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.11 of the Registrant’s Amendment No.
+Added: 10.3 Form of Nonqualified Stock Option Grant Notice and Nonqualified Stock Option Agreement under 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.11 of Globus Medical Inc.’s Amendment No.
1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
−Removed: Form of Indemnification Agreement (incorporated by reference to Exhibit 10.18 of the Registrant’s Amendment No.
+Added: 10.4 Form of Indemnification Agreement (incorporated by reference to Exhibit 10.18 of Globus Medical Inc.’s Amendment No.
1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
−Removed: Form of No Competition and Non-Disclosure Agreement (incorporated by reference to Exhibit 10.19 of the Registrant’s Amendment No.
+Added: 10.5 Form of No Competition and Non-Disclosure Agreement (incorporated by reference to Exhibit 10.19 of Globus Medical Inc.’s Amendment No.
1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
1 unchanged sentence
and Daniel T.
−Removed: Scavilla (incorporated by reference to Exhibit 10.1 to our Form 10-Q filed with the SEC on May 4, 2016).
+Added: Scavilla (incorporated by reference to Exhibit 10.1 to Globus Medical Inc.’s Form 10-Q filed with the SEC on May 4, 2016).
10.7 Executive Employment Agreement, dated August 5, 2020 by and between Globus Medical, Inc.
−Removed: and Kelly Huller (incorporated by reference to Exhibit 10.1 to our Form 10-Q filed with the SEC on August 5, 2020).
+Added: and Kelly Huller (incorporated by reference to Exhibit 10.1 to Globus Medical Inc.’s Form 10-Q filed with the SEC on August 5, 2020).
10.8 Executive Employment Agreement, dated August 5, 2020 by and between Globus Medical, Inc.
−Removed: and Keith Pfeil (incorporated by reference to Exhibit 10.2 to our Form 10-Q filed with the SEC on August 5, 2020).
+Added: and Keith Pfeil (incorporated by reference to Exhibit 10.2 to Globus Medical Inc.’s Form 10-Q filed with the SEC on August 5, 2020).
10.9 Globus Medical, Inc.
−Removed: 2021 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to our Form 8-K filed with the SEC on June 5, 2024).
+Added: 2021 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to Globus Medical Inc.’s Form 8-K filed with the SEC on June 5, 2024).
10.10 Globus Medical, Inc.
−Removed: 2021 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference to Exhibit 99.5 to our Form S-8 filed with the SEC on December, 16, 2021).
+Added: 2021 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference to Exhibit 99.5 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.11 Globus Medical, Inc.
−Removed: 2021 Equity Incentive Plan Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 99.6 to our Form S-8 filed with the SEC on December, 16, 2021).
+Added: 2021 Equity Incentive Plan Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 99.6 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.12 Globus Medical, Inc.
−Removed: 2021 Equity Incentive Plan Restricted Stock Agreement (incorporated by reference to Exhibit 99.7 to our Form S-8 filed with the SEC on December, 16, 2021).
+Added: 2021 Equity Incentive Plan Restricted Stock Agreement (incorporated by reference to Exhibit 99.7 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.13 Globus Medical, Inc.
−Removed: 2021 Equity Incentive Plan Incentive Stock Option Agreement (incorporated by reference to Exhibit 99.8 to our Form S-8 filed with the SEC on December, 16, 2021).
−Removed: Indenture, dated as of March 2, 2020, between NuVasive and the Trustee (incorporated by reference to Exhibit 4.1 to NuVasive, Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
−Removed: First Supplemental Indenture, dated as of September 1, 2023, among Globus, NuVasive and the Trustee (incorporated by reference to Exhibit 4.2 to Globus Medical, Inc.'s Current Report on Form 8-K filed with the SEC on September 1, 2023).
+Added: 2021 Equity Incentive Plan Incentive Stock Option Agreement (incorporated by reference to Exhibit 99.8 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.14 Credit Agreement, dated as of September 27, 2023, by and among the Company, U.S.
5 unchanged sentences
and Branch Medical Group, as guarantors (incorporated by reference to Exhibit 10.2 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on October 2, 2023).
−Removed: 2014 Equity Incentive Plan (incorporated by reference to Exhibit A to NuVasive Inc.'s Definitive Proxy Statement filed with the Commission on March 27, 2014) (incorporated by reference to Exhibit 10.5 to Globus Medical, Inc.'s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
+Added: 10.16 2014 Equity Incentive Plan (incorporated by reference to Exhibit A to NuVasive Inc.’s Definitive Proxy Statement filed with the Commission on March 27, 2014) .
10.17 2015 Ellipse Technologies, Inc.
37 unchanged sentences
10.48 Warrant Guarantee Agreement, dated as of September 1, 2023, between Royal Bank of Canada and the Company (incorporated by reference to Exhibit 10.37 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
+Added: 10.49 Voting and Support Agreement, dated as of February 6, 2025, by and among Globus Medical, Inc., Nevro Corp., and other signatories thereto (incorporated by reference to Exhibit 10.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on February 6, 2025).
19.1 Globus Medical, Inc.
−Removed: Insider Trading Policy, adopted as of February 18, 2024
+Added: Insider Trading Policy, adopted as of February 18, 2024 (incorporated by reference to Exhibit 19.1 to Globus Medical, Inc.’s Annual Report on Form 10-K filed with the SEC on February 20, 2025).
21.1* Subsidiaries of Globus Medical, Inc.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Globus Compensation Recoupment Policy
−Removed: XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
−Removed: XBRL Taxonomy Extension Schema Document
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: XBRL Taxonomy Extension Label Linkbase Document
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: XBRL Taxonomy Extension Definition Linkbase Document
+Added: 97.1 Gl obus Compensation R ecoupment Po licy ( incor porated by reference to Exhibit 97 .1 to Globus Medical, Inc's Annual R e port o n F orm 10-K filed with the SEC on February 20, 2025).
+Added: 101.INS* XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
+Added: 101.SCH* XBRL Taxonomy Extension Schema Document
+Added: 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
+Added: 101.LAB* XBRL Taxonomy Extension Label Linkbase Document
+Added: 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
+Added: 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
6 unchanged sentences
GLOBUS MEDICAL, INC.
−Removed: February 20, 2025
−Removed: /s/ DANIEL T.
−Removed: Chief Executive Officer
+Added: February 24, 2026 /s/ KEITH W.
+Added: President and Chief Executive Officer
(Principal Executive Officer)
−Removed: February 20, 2025
−Removed: /s/ KEITH PFEIL
−Removed: Chief Financial Officer and Chief Operating Officer
−Removed: Chief Accounting Officer
−Removed: Executive Vice President
+Added: February 24, 2026 /s/ KYLE R.
+Added: Chief Financial Officer
(Principal Financial Officer)
+Added: Senior Vice President
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
−Removed: /s/ DANIEL T.
−Removed: President and Chief Executive Officer
−Removed: February 20, 2025
+Added: SIGNATURE TITLE DATE
+Added: President and Chief Executive Officer February 24, 2026
(Principal Executive Officer)
−Removed: /s/ KEITH PFEIL
−Removed: Chief Financial Officer and Chief Operating Officer
+Added: Chief Financial Officer
February 24, 2026
−Removed: Chief Accounting Officer
−Removed: Senior Vice President
(Principal Financial Officer)
−Removed: Executive Chairman and Director
−Removed: February 20, 2025
−Removed: February 20, 2025
−Removed: /s/ ROBERT DOUGLAS
−Removed: February 20, 2025
−Removed: Robert Douglas
+Added: Senior Vice President
+Added: PAUL Executive Chairman and Director February 24, 2026
+Added: DAVIDAR Director February 24, 2026
+Added: /s/ ROBERT A.
+Added: Director February 24, 2026
/s/ DANIEL T.
−Removed: February 20, 2025
−Removed: February 20, 2025
−Removed: February 20, 2025
+Added: LEMAITRE Director February 24, 2026
+Added: RHOADS Director February 24, 2026
+Added: TOBIN Director February 24, 2026
/s/ STEPHEN T.
−Removed: February 20, 2025
−Removed: February 20, 2025
+Added: ZARRILLI Director February 24, 2026
+Added: DEFORD Director February 24, 2026
/s/ DANIEL J.
−Removed: February 20, 2025
+Added: WOLTERMAN Director February 24, 2026
/s/ LESLIE V.
−Removed: February 20, 2025
+Added: NORWALK Director February 24, 2026
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.